摘要
目的探究塞来昔布对老年三阴性乳腺癌患者血清白介素-6（IL-6）及白介素-8（IL-8）水平影响。方法收集2013年3月~2015年4月浙江省嘉兴市第二医院肿瘤科收治的老年三阴性乳腺癌患者64例,随机分为对照组和试验组,各32例。2组患者均给予TAC方案,对照组在化疗结束后给予枸橼酸他莫昔芬片10 mg口服,2次/天,试验组在化疗结束后给予塞来昔布胶囊200 mg口服,2次/天。2组患者1个疗程均为3周,共治疗6个疗程。治疗结束后对比分析2组临床疗效、血清IL-6、IL-8、雌激素水平以及不良反应。结果治疗后,试验组临床总有效率显著高于对照组（93.75%vs.75.00%,χ2=4.267,P〈0.05）,治疗后2组血清IL-6、IL-8、雌酮（oestrone,E1）、雌二醇（estradiol,E2）水平下降（P〈0.05）,促卵泡生成素（follicle-stimulating hormone,FSH）、促黄体生成素（luteinizing hormone,LH）水平上升（P〈0.05）,与对照组相比,试验组血清IL-6、IL-8、E1、E2水平较低（P〈0.05）,FSH、LH水平较高（P〈0.05）。与对照组相比,试验组总不良反应发生率较低（21.88%vs.56.25%,χ2=7.94,P〈0.05）。结论塞来昔布对老年三阴性乳腺癌的临床疗效显著,有效降低血清IL-6、IL-8水平,调节机体雌激素水平,药物安全性高。
Objective To explore the effect of celecoxib on serum levels of IL-6 and IL-8 in patients with senile triple negative breast cancer.Methods 64 cases with senile triple negative breast cancer collected from March 2013 to April 2015 in our hospital,and randomly divided into control group and experimental group,32 cases in each group. The two groups received TAC scheme,the control group received tamoxifen citrate tablets 10 mg orally,twice daily and the experimental group received celecoxib capsules 200 mg orally,twice daily,at the end of the chemotherapy,for a consecutive treatment of 6 courses,three weeks as one course. The clinical curative effect,serum interleukin-6 and interleukin-8,estrogens levels and adverse reactions were compared between two groups post-treatment. Results After treatment,the total effective rate in experimental group was higher than that in control group（ 93. 75% vs. 75. 00%,χ2= 4. 267,P〈0. 05）. The serum levels of IL-6,IL-8,oestrone（ E1） and estradiol（ E2） decreased（ P〈0. 05）and the serum levels of follicle-stimulating hormone（ FSH） and luteinizing hormone（ LH） increased in two groups post-treatment（ P〈0. 05）. The total adverse reactions in experimental group was lower than that in control group（ 21. 88% vs. 56. 25%,χ2= 7. 94,P〈0. 05）. Conclusion Celecoxib has the significant efficacy in the treatment of patients with senile triple negative breast cancer,could reduce serum IL-6 and IL-8 levels and regulate estrogens levels with fewer adverse reactions.
出处
《中国生化药物杂志》
CAS
2016年第3期40-42,共3页
Chinese Journal of Biochemical Pharmaceutics
基金
浙江省自然科学基金(LY12H29004)
